Table 4.

Cases for Which Germline Genetic Information Affected Discussion or Implementation of Therapeutic Strategies

Outcome	Cases, No.
	With Clinically Actionable Mutations (n = 182)	With Clinically Actionable Mutations Incremental to Phenotype-Based Assessment (n = 101)
Discussion or initiation of targeted therapy	38	17
Targeted therapy administered	11a	6a
PARP inhibitors	9b	4c
Platinum-based therapy	4d	2e

Abbreviation: PARP, poly adenosine diphosphate–ribose polymerase.

^aNot including 1 case of hypermutated prostate cancer with a PMS2 variant with planning of immunotherapy treatment in progress. Patients may have received more than 1 targeted therapy.

^bIncludes 3 cases of prostate cancer with ATM mutations, 2 cases of prostate cancer with BRCA2 mutations, and 1 case of biliary cancer and 3 cases of pancreatic cancer with BRCA1/2 mutations.

^cIncludes 1 case of biliary cancer with BRCA2 mutation, 1 case of pancreatic cancer with BRCA2 mutation, and 2 cases of prostate cancer with ATM mutations.

^dIncludes 3 cases of prostate cancer with ATM and BRCA2 mutations and 1 case of pancreatic cancer with BRCA1 mutation (2 of these cases also received PARP inhibitors).

^eIncludes 1 case of prostate cancer with ATM mutation and 1 case of prostate cancer with BRCA2 mutation.